Incyte’s Vitiligo Treatment Demonstrates Efficacy in Phase 3 Program
Incyte Corporation (Nasdaq: INCY) has announced new results of a long-term extension from its pivotal Phase 3 program assessing Opzelura® (ruxolitinib) cream in patients with non segmental vitiligo. Results were presented this week in a late-breaking news session at the 2023 European Academy of Dermatology and Venereology Congress held in Berlin.
Patients who initially experienced limited or no facial or total body repigmentation at six months achieved improved repigmentation after continued treatment with Opzelura for up to two years.
Dr. Albert Wolkerstorfer, Netherlands Institute for Pigment Disorders, Department of Dermatology, University of Amsterdam, said, “With this analysis, we were able to more closely examine the impact of continued treatment with Opzelura in patients who showed limited to no improvements in facial or total body repigmentation following an initial six-month course of treatment. These data highlight the importance of continuing treatment with Opzelura in patients with vitiligo, even when minimal or no repigmentation is achieved after six months of treatment.”
Opzelura was well-tolerated with no serious treatment-related adverse events.
The treatment is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
Opzelura is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis. In Europe, it is approved for the treatment of non-segmental vitiligo for patients 12 years and older.
Vitiligo is a chronic autoimmune disease characterized by depigmentation of skin that results from the loss of pigment-producing cells known as melanocytes. It affects more than 1.5 million people in the United States.
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
About Incyte Dermatology
Incyte’s science-first approach and expertise in immunology has formed the foundation of the company. Today, we are building on this legacy as we discover and develop innovative dermatology treatments to bring solutions to patients in need. Our research and development efforts in dermatology are initially focused on leveraging our knowledge of the JAK-STAT pathway. We are exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo, hidradenitis suppurativa, lichen planus, lichen sclerosus and prurigo nodularis.